High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma-Reference-Cited by-同舟云学术

High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma

Published:2018-04-19 Issue:10 Volume:53 Page:1311-1318
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Jodele Sonata,Dandoy Christopher E.^ORCID,Myers Kasiani,Wallace Gregory,Lane Adam,Teusink-Cross Ashley,Weiss Brian,Davies Stella M.

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0159-8.pdf

Reference32 articles.

1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–73.

2. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA. et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999–1008. https://doi.org/10.1016/S1470-2045(13)70309-7 .

3. Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M. et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000;18:2567–75.

4. Desai AV, Heneghan MB, Li Y, Bunin NJ, Grupp SA, Bagatell R. et al. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Bone Marrow Transplant. 2016;51:1204–10. https://doi.org/10.1038/bmt.2016.84 .

5. Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M. et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82:638–44. https://doi.org/10.1097/01.tp.0000230373.82376.46 .

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric Transplant Associated Thrombotic Microangiopathy Healthcare Utilization and Implications of Eculizumab Therapy;Blood Advances;2023-12-28

2. The Impact of 131I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma;Children;2023-12-18

3. Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians;Journal of Intensive Care Medicine;2023-11-21

4. Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA;Blood Journal;2023-11-09

5. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?;Frontiers in Pharmacology;2023-10-26